Author Archives: admin


How Cell Phone Addiction Is Making You a Victim of Major Disabilities – Entrepreneur

To all the cellphones lovers out there, yes there are now cellphone related syndromes and they ain't good

October29, 20197 min read

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Cellphones and handheld gadgets have become an inseparable part of our busy lives. In addition to being the handiest and effective way of communication, they have become our quintessential partner. They frequently double up as a utility gadget an alarm clock, a calculator, a handy internet browser, etc. The numerous applications offer virtually unlimited uses. You can use your cellphone to control the lights in your home, play your favorite music or even monitor and track your physiology when you sleep. Your phone is now responsible for your smart living. All these features may seem overwhelming and extremely useful, but they come at a hidden cost. It is not the obvious cost you pay for your device and data connection but the hidden cost which you must pay as the cellphone invades your life.

What if we tell you there is something called as cellphone pain syndrome and you are suffering from it? Dont believe us?

Entrepreneur India got in a conversation with Dr. Sidharth Verma, Consultant Interventional Spine & Pain Physician, Masina Hospital who gave us an insight on the common cellphone syndromes that we suffer from and what it leads to.

Giving an introduction about it he said, While the symptoms of cellphone pain syndromes might seem different, they are a connected group that consistently occurs together as soon as the relationship with the cellphone is consummated. It is estimated that the average person spends almost three hours a day on the mobile or hand-held devices.

Repetitive use of handheld devices especially in awkward positions like sitting on a bus or standing in a train, puts undue pressure on the bones and muscles of the neck. Many studies have estimated that stress levels increase five to ten times while looking down at a smartphone or tablet.

Multiply the effect with long duration, add some bumps along the car/bus ride and you have a recipe for this lifestyle illness. Symptoms are neck pain, early morning stiffness and inability to look down on the screen for too long. Severe cases may have headache, dizziness, arm pain as well as upper back pain. The muscle imbalances can result in low back pain as well, said Dr. Sidharth Verma.

A recent study has linked the posture changes caused by the text neck syndrome to heart disease! Mild symptoms can be managed by rest (and avoiding forward bending of the neck), anti-inflammatory medicines and cold compressions. Exercises can help, he added.

However, unresolved symptoms should be quickly treated by a pain physician. The use of advanced image-guided procedures has made minimally invasive treatment possible for these pain syndromes.

Another simple way is to either look down with only your eyes (keeping your head at the same level) or simply lift the phone to the eye level, instead of looking down by tilting your head.

This one is quite popular with various names like the BlackBerry thumb, SMS thumb, Gamer's thumb, Washerwoman's sprain, radial styloid tenosynovitis, de Quervain disease/ tenosynovitis, designer's thumb, mother's wrist or mommy's thumb. It is caused by inflammation in the tendons which control the movements of the thumb.

Overuse of the same actions over some time can worsen the symptoms. Mild symptoms can be managed with rest (most important), anti-inflammatory medicines (oral or around the affected region) and cold compression. Severe symptoms not responding to these measures may need advance treatment modalities like Pulsed radiofrequency current or ultrasound-guided platelet-rich plasma (PRP) injections, said Dr. Verma.

After the neck, wrist, and thumb, elbows are the most commonly affected areas. Also known as the cubital tunnel syndrome, the symptoms include burning, tingling, numbness or weird sensations on the inner side of the arm and elbow.

Verma highlighted other symptoms like weakness in the affected arm and inability to perform simple tasks like opening bottle lids. Treatment is essential, if left untreated, it may result in permanent weakness and clawing of fingers. Treatment ranges from lifestyle modification to interventional pain procedures however early treatment always leads to better results.

This is the second most common syndrome after neck pain occurs when the median nerve gets compressed at the wrist. This results in tingling, numbness, weakness, and pain in the thumb, middle and index fingers.

If you are a user of computer keyboards, you are more prone to this than anyone else. These symptoms may become permanent and must be treated by the earliest.

There are some things one needs to keep in mind when it comes to treating it. Treatment ranges from physical measures like exercises, habit modification and heat/cold application to interventional ultrasound-guided median nerve release. Your pain Physician can treat the condition and formulate a recovery plan, said Dr. Verma.

In addition to the above, cellphones are known to cause repetitive strain injuries in susceptible individuals.

Cellphone usage results in interference with sleep patterns and causes cognitive dysfunction. Emotional symptoms like lack of self-esteem, need for constant motivation and even depression can be attributed to these devices. Mobile gaming can result in dangerous consequences. World Health Organization has recognized gaming addiction as a mental disorder.

Giving a perfect example Dr. Verma said, Youngsters are very sensitive to the number of likes, shares and retweets on their posts and this social media takes a toll on their ability to forge long-lasting and meaningful relations. These effects can be minimized only by limiting cellphone usage and engaging in real-world physical activities.

Constantly staring at the cellphone screen can result in dry eyes and lessen tearing. While viewing content on your cellphone, one often forgets to blink. This can cause strain on the eyes and result in an increased incidence of infections. The blue-toned light of these handheld devices can result in early macular degeneration and blindness. Staring at the narrow screen (even widescreens are narrow compared to the normal field of vision) leads to eye fatigue and blurry vision.

All these symptoms are preventable but difficult to treat once they become chronic. Some tips are to increase text size, reduce screen brightness, use artificial tears (to help with dryness), blink frequently and take frequent breaks. If symptoms persist, you might need to visit an ophthalmologist, said Dr. Verma

If you are putting your phone in tight trousers, you greatly increase your chances of having what is known as the Tight-thigh syndrome. Also known as meralgia paraesthetica, this is a condition seen mostly in obese people with tight clothing. However, putting objects in your front pocket increases the risk manifold.

Symptoms include tingling, numbness and burning sensation in the outer thigh. Treatment revolves around lifestyle modification, radio frequency modulation, and ultrasound-guided cryotherapy.

Dr. Verma points out that, Surgery is overkill for these conditions and your pain physician can help with the non-surgical treatment options available. Many of these treatment options are minimally invasive but highly effective with excellent results. In case the usage pattern and posture is not modified, the symptoms can occur again.

Also Read:#9 Tips & Tricks to Not Let the Phone Addiction Destruct Your Body

Read this article:
How Cell Phone Addiction Is Making You a Victim of Major Disabilities - Entrepreneur

Dr Batra’s have launched a new genetics-based therapy that predicts future diseases – Gulf Today

Dr Mukesh Batra, the owner of Dr Batras clinics.

Mitchelle DSouza, Sub-editor/Reporter

The founder and chairman of Dr Batras group of companies, Dr Mukesh Batras name has become a byword for homeopathy.

The pioneering Indian doctor-cum-entrepreneur has built a legacy which includes a network of clinics, day-care aesthetic centres, and health and wellness products.

We caught up with Dr Batra at his Healthcare City clinic in Dubai, where he spoke at length about the workings of homeopathy and introduced us to the new Geno-Homeopathy treatment launched by the brand.

Can you explain what homeopathy treatment is for those who dont have a clear understanding? How does it work in comparison to conventional medicine?

Theres actually a misconception that its not well known. For emergencies and conventional problems, allopathy is the go-to. Like a heart attack, surgeries, gunshot wounds and so on.

However, homeopathy is safe for anything that is chronic and long lasting such as psychosomatic problems like stress, anxiety, and depression related issues; allergies, skin and hair problems.

We treat a wide range of illnesses such as asthma, arthritis, anxiety, depression, backache, cervical spondylitis, kidney stones in primary stage, warts, piles, PCOD, nasal polyps etc.

It has no side-effects and is completely painless and non-invasive. It goes to the root of the problem, nipping it in the bud, rather than just supressing it temporarily with pain killers.

"People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

Is it true that homeopathy is slower in addressing an ailment in comparison to allopathy?

Its partly true, but not entirely. If you come to allopathy for a chronic sinus problem, you pop a pill and supress it. Similarly for a skin allergy, an ointment will supress the symptoms. The moment you stop, it flares up again.

So when you look at suppression, it is quick in allopathy, but thats not a cure. In conventional medicine, treatment is as slow as homeopathy or maybe even slower

For instance, a patient may be supressing his/her migraine or skin problem for the last 10 years with allopathy by taking pain killers and anti-inflammatories but without a proper solution.

However, if he/she were to take homeopathy for just 10 months, it would cure it, and hence that makes it much faster and effective as it gets to the root of the cause.

The reason it may feel seemingly long is because most illnesses are chronic, long-standing and deep-rooted.

Geno-Homeopathy treatment employs a gene test to predict, pre-empt and treat an illness. Charles Bertram/TNS

Can you give us an insight into the new Geno-Homeopathy treatment launched in the UAE?

As you may be aware, genetic DNA studies have been around for some years and have become more popular off late, thanks to Angelina Jolie creating awareness by positively testing herself for a cancer gene.

This helps predict and pre-empt an illness. How this works is that you have genes that are inherited, with 99.9 per cent of them being normal. But 0.1 per cent genes can be faulty and that percentage decides what diseases we carry.

A gene is like a finger print, it never changes. So just like you would use your finger print or pupil for identity, this is used for gene mapping through a simple sputum test. Now that 0.1 percentage gene decides how healthy I can be and which diseases I am likely to suffer from.

So with Geno-Homeopathy we can now analyse those 0.1 per cent genes. We completed one year in India in September and did 15,000 cases of genetic mapping.

This technique gives you your disease propensity and can tell you, for example, whether youll go bald five or 10 years from now; if youre prone to heart attack or diabetes it will tell you when youre likely to get it.

Post an analysis, a homeopathic treatment is offered to the patient to treat a condition. So this can be almost life-saving and is now within peoples reach in the UAE.

Angelina Jolie found out through genetic testing similar to Geno-Homeopathy that she is at a high risk of developing breast cancer.Marechal Aurore/TNS

There are a lot of cynics out there who question the scientific basis of homeopathy. What do you have to say to that?

A research we conducted three to four years ago found that a majority of people in Indian metros were taking homeopathy as the first choice of treatment. Pharma is growing at 10 per cent while homeopathy is growing at 30 per cent all over the world.

People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

To give you a little perspective, there are around 300 people dying of drug reaction in America alone everyday which is equal to a Boeing crash. But it doesnt get as much attention, which can be pinned on the strong medical lobby.

So theres a gradual shift happening from allopathy to homeopathy not just in India but all over the world.

That being said, there are a lot of cynics and the lobbies that plant various stories. In spite of all this homeopathy is growing exponentially. The proof of the pudding is in eating it, so people should give it a try before denouncing it.

See the article here:
Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today

Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell…

CAMBRIDGE, Mass., Oct. 29, 2019 /PRNewswire/ -- Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing. The company's novel approach focuses on targeting hepcidin, a key regulator of iron metabolism, as a treatment for inherited and acquired anemias. The Series A financing was led by Novo Holdings A/S along with Access Biotechnology and founding investor Atlas Venture. Atlas seeded the company in 2017. Donald Nicholson, former CEO of Nimbus Therapeutics, is joining as the company's executive chairman.

"We have accumulated a wealth of experience and new insights into hepcidin biology and its role in hematologic diseases," said Brian MacDonald, founder and interim CEO of Disc Medicine. "We are harnessing these insights to develop first-in-class therapies targeting the hepcidin pathway to address a wide range of anemias."

Hepcidin is a small peptide hormone produced in the liver which acts as a key regulator of systemic iron metabolism. Dysregulation of hepcidin leads to either iron overload or iron deficiency, and chronic hepcidin dysregulation is observed in conditions associated with ineffective erythropoiesis, a state of impaired red blood cell production. Ineffective erythropoiesis disorders such as myelodysplastic syndromes, thalassemia, and anemia of chronic disease are often characterized by severe anemia that can have a significant impact on lifespan and quality of life.

Disc Medicine is advancing two therapeutic programs focused on regulating hepcidin expression - a novel, orally administered matriptase-2 inhibitor which increases hepcidin expression to treat iron loading anemias, and a hemojuvelin antagonist monoclonal antibody to reduce hepcidin expression and address anemia in a range of chronic inflammatory and hematologic diseases.

"Disc Medicine is poised to transform the treatment of these hematologic diseases with its novel approach to targeting hepcidin biology," said Kevin Bitterman, founding investor, Atlas Venture. "Over the past fifty years, the treatment of anemia has relied largely on blood transfusions which can be burdensome and even impair patient outcomes. Further, options are limited for patients who do not receive transfusions. With the launch of Disc Medicine, we seek to change the treatment paradigm with a new way to address the ineffective erythropoiesis that is associated with these diseases."

"We are pleased to support the Disc Medicine team in developing novel drugs to modulate the hepcidin axis to address multiple hematological diseases," said Nilesh Kumar, Partner, Novo Ventures. "The linearity of the science and the progress made by the team on targets backed by human genetics is an exciting development in this space."

Disc Medicine was founded in 2017 by Atlas Venture and Brian MacDonald. The Board of Directors is chaired by Donald Nicholson and includes Kevin Bitterman, Nilesh Kumar and Liam Ratcliffe. The Disc team is supported by world class medical advisors including Stefano Rivella, PhD, Professor of Pediatrics at The Children's Hospital of Philadelphia, Mark Fleming, MD, DPhil, Pathologist-in-Chief at Boston Children's Hospital and S. Burt Wolbach Professor of Pathology at Harvard Medical School, Srdan Verstovsek, MD, PhD, professor, Department of Leukemia at The University of Texas MD Anderson Cancer Center and Uma Sinha, PhD, chief scientific officer at BridgeBio Pharmaceuticals.

About Disc Medicine Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. For more information, visit http://www.discmedicine.com.

About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, the company has been building breakthrough biotech startups since 1993. Atlas works side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit http://www.atlasventure.com.

About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. For more information, visit http://www.novoholdings.dk.

About Access Biotechnology Access Biotechnology is the life science investment arm of Access Industries. The investment strategy is broad, long term and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation and company expansion. Our approach is based on rigorous diligence and we provide value-added support from our extensive experience and networks.

View original content to download multimedia:http://www.prnewswire.com/news-releases/disc-medicine-completes-50-million-series-a-financing-led-by-novo-holdings-as-to-advance-new-therapies-addressing-ineffective-red-blood-cell-production-300946714.html

SOURCE Disc Medicine

More here:
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell...

School of Medicine Presents Its Highest Award to Immune System Researcher – UPJ Athletics

RuslanMedzhitov,a researcher who transformed the understanding of how the immune system detects infections, which paved the way for therapies for a wide range of diseases, received the 2019Dickson Prize in Medicine,theUniversity of Pittsburgh School of Medicineshighest honor.

The prize is awarded annually to an American biomedical researcher who has made significant, progressive contributions to medicine. The award consists of a specially commissioned medal, a $50,000 honorarium and an invitation to present the keynote lecture during the Universitys annual campus-wide showcase of scientific research.

It is difficult to overstate the impact that Ruslans work has had in how we perceive the role of the immune system in health and disease, saidArthur S. Levine, Pitts senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of Medicine. We are beginning to recognize that the immune system is intimately linked to almost every human disease, and his discoveries have contributed significantly toward that understanding.

Medzhitov, Sterling Professor of Immunology atYale University School of Medicineand aHoward Hughes Medical Instituteinvestigator, said, I feel extremely honored to receive this prestigious award. None of this would be possible without my incredible mentors and trainees who I have been fortunate to work with.

In 1997, Medzhitov, together with his mentor at Yale, the late Charles A. Janeway Jr.. discovered a protein on the cells surface called Toll-like receptor 4 (TLR4) and demonstrated its role in activation of an immune response. This discovery proved to be the missing link of molecular pathways that connect the bodys recognition of a pathogen to its defensive response.

He also is credited with many fundamental discoveries concerning the broader importance of Toll-like receptors in controlling adaptive immunity, infections, chronic inflammation and tumor growth. Following these advances, drugs are actively being developed to target these Toll-like receptors in hopes of treating cancer, sepsis and inflammatory disease, among others.

Medzhitovaccepted the award duringScience 2019: Question, the regions preeminent showcase of the latest research in science, engineering, medicine and computation, held from Oct. 17 to 19 in Pittsburgh, delivering the Dickson Prize in Medicine Lecture at the opening plenary session.

Medzhitov was born in Tashkent, Uzbekistan, and earned a BS at Tashkent State University before completing a PhD in biochemistry at Moscow University in 1990. He performed his postdoctoral studies at Yale University Medical School.

Medzhitov has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Russian Academy of Science and is a fellow of the American Association for the Advancement of Science. In 2010, he received the prestigious Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research for elucidating the mechanisms of innate immunity. His numerous other awards include the 2011 Shaw Prize in Life Science and Medicine and the Vilcek Foundation, Lurie and Else Krner-Fresenius-Stiftung Prizes, all in 2013.

View post:
School of Medicine Presents Its Highest Award to Immune System Researcher - UPJ Athletics

Protein vital for T cell formation and function revealed – Drug Target Review

Researchers have discovered a protein that is required for T cell biological processes; they have also demonstrated the mechanism behind the protein.

A gene and family of proteins that are critical for the formation and function of T cells has been identified by researchers. According to the team, their discovery could lead to new therapies for immune diseases such as multiple sclerosis.

when AP-1 binds to certain chromatin locations, it does so in conjunction with its molecular partner

The study was conducted at the Cincinnati Childrens Hospital Medical Center, US.

The researchers demonstrated that the transcription factor activator protein 1 (AP-1) is needed for microbiological processes in the nucleus of early immature T cells.

In the early stages of development of CD4 T cells, the researchers profiled chromatin, the DNA structure that condenses in the cell nucleus. They completed this using chromatin immunoprecipitation (ChIP-seq) and assay for transposase accessible chromatin (ATAC-Seq), which analysed all the protein interactions with DNA.

AP-1 was found to aid in opening up the chromatin, stimulating a cascade of genetic and molecular mechanisms that co-operate to form cells.

Inhibiting AP-1, the researchers revealed that the chromatin failed to open; this meant the T cells did not form or function properly.

Another finding was that when AP-1 binds to certain chromatin locations, it does so in conjunction with its molecular partner, nuclear factor of activated T cells (NFAT1).

At risk loci, where chromatin are prone to genetic mutations or linked to multiple immune diseases, AP-1 was found to accumulate and influence molecular processes.

Our findings allow us to conduct new studies into whats happening molecularly and mechanistically at these risk loci when the mutations are present and when they are not, saidDr Artem Barski, lead study investigator. Our goal is to use this mechanistic knowledge to eventually develop protective vaccines, anti-cancer immune therapies or reduce pathologic immune responses like asthma, allergies and autoimmunity.

The results were published in the Journal of Experimental Medicine.

Go here to read the rest:
Protein vital for T cell formation and function revealed - Drug Target Review

Micheliolide Inhibits Liver Cancer Cell Growth Via Inducing Apoptosis | CMAR – Dove Medical Press

Lili Yu,1,2,* Wancheng Chen,2,* Qingshuang Tang,2,* Kai-Yuan Ji1

1The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033, Peoples Republic of China; 2Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Kai-Yuan JiThe Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518033, Peoples Republic of ChinaTel +8675515625055871Email 369027938@qq.com

Purpose: Micheliolide (MCL) is an effector compound of the flower which has been traditionally used to treat inflammation and cancer patients in oriental medicine. MCL has killing effects on several cancer and immune cells by modulating apoptosis, cell cycle, and metabolism. However, the detail of the mechanisms of anti-cancer activity remains to be elucidated and the effect on liver cancer cells is unknown.Methods: Cell proliferation was determined by CCK8 and clone formation assay. The xenograft liver cancer model formed by injecting Huh7 cells into NUDE mice was used to evaluate the effects of MCL on liver cancer cells in vivo. We evaluated the stemness of cells with spheroid formation assay and flow cytometry assay. The apoptosis was determined by Annexin V assay. F-actin staining and ROS were performed to detect the impairment of the F-actin cytoskeleton and mitochondria.Results: Here, we first show that MCL inhibits liver cancer cells both in vivo and in vitro by triggering apoptosis which was reduced by anti-oxidant, but not cell-cycle arrest. In addition, MCL induces mitochondrial ROS and caspase-3 activation. Also, we found that the aggregation of mitochondria and the perturbation of F-actin fibers in the MCL-treated liver cancer cells coincidently occurred before the induction of apoptosis and mitochondrial ROS.Conclusion: These results suggest that F-actin perturbation is involved in impaired mitochondria and apoptosis. Therefore, MCL can be a potent therapeutic reagent for liver cancer, primarily targeting the actin cytoskeleton.

Keywords: Micheliolide, liver cancer, apoptosis, ROS, actin cytoskeleton

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Micheliolide Inhibits Liver Cancer Cell Growth Via Inducing Apoptosis | CMAR - Dove Medical Press

First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma – Business Wire

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited off-the-shelf CAR T-cells (UCART), today announced the Company has dosed the first patient in its UCARTCS1 clinical trial, MELANI-01, the first allogeneic off-the-shelf CAR-T product candidate the U.S. Food and Drug Administration (FDA) has cleared to enter into clinical development for relapsed/refractory multiple myeloma (R/R MM). The UCARTCS1 clinical trial is a Phase 1 dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1 cells in R/R MM patients.

This first patient dosing for our MELANI-01 clinical trial is an important advancement, as our team has worked tirelessly to develop and take the CS1 target from the lab to the clinic, said Dr. Andr Choulika, Chairman and CEO, Cellectis. In taking this next clinical step, we look forward to deepening our understanding of UCARTCS1 as a potential new treatment option for relapsed/refractory multiple myeloma patients in the future.

The MELANI-01 clinical trial is currently open at MD Anderson Cancer Center in Houston, Texas, under the supervision of Dr. Krina Patel, Principal Investigator, Study Coordinating Investigator, Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at MD Anderson Cancer Center, as well as Hackensack Meridian in New Jersey under the supervision of Dr. David Siegel, Director of the Multiple Myeloma Institute at John Theurer Cancer Center (JTCC) at Hackensack University Medical Center. Another site is planned to open at Weill Cornell Medicine in New York under the leadership of Dr. Adriana Rossi, Associate Clinical Director, Myeloma Center and Assistant Professor of Medicine, Division of Hematology and Medical Oncology.

About Multiple Myeloma (MM)Multiple myeloma is a cancer that affects a type of white blood cells called plasma cells that are specialized mature B cells, which secrete antibodies to combat infections. Multiple myeloma is characterized by the uncontrolled proliferation of neoplastic plasma cells in the bone marrow, where they overcrowd healthy blood cells. Although MM is a chronic disease and an exact cause has not yet been identified, researchers have made significant progress over the years in managing the disease through better understanding MMs pathophysiology. The progress in finding a cure needs to be continued as The American Cancer Society estimates that 32,110 new cases of MM will be diagnosed, and 12,960 deaths are expected to occur in 2019 in the U.S. alone.

About UCARTCS1UCARTCS1 is an allogeneic, off-the-shelf, gene-edited T-cell product candidate designed for the treatment of multiple myeloma. CS1 (SLAMF7) is highly expressed on MM tumor cells and is an attractive target. The limitation so far has been the presence of the CS1 target on the surface of T-cells, which has hindered the access to CAR-Ts. For example, the introduction of a CAR construct in T-cells induces cross T-cell reactivity and leads to destruction of the CS1+ T-cell population during manufacturing. Cellectis solved this issue by using TALEN gene editing to knock out the CS1 gene from T-cells before introducing the CS1 CAR construct.

About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 19 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

DisclaimerThis press release contains forward-looking statements that are based on our managements current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risk factors that may affect company business and financial performance is included in Cellectis Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2018 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Follow this link:
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma - Business Wire

Cell Membrane Protein Identified as "Crucial" in Development of Liver Cancer – Technology Networks

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have just described for the first time the crucial involvement of a cell membrane protein in the development and progression of liver cancer, according to an article published in theJournal of Hepatology. This protein, called clathrin, is known for its key role in the process of internalization of molecules from the extracellular space into the cell, called endocytosis. In this process, the cell membrane folds creating vesicles with a cladded structure. Thanks to the new results, analyzing the levels of clathrin expression in biopsies of hepatocellular carcinoma patients will help select those patients who will benefit from a much more targeted and personalized therapy.

The research team, led by Dr. Isabel Fabregat, who is a professor at the Faculty of Medicine and Health Sciences of the University of Barcelona and a researcher at the CIBER of Hepatic and Digestive Diseases, has shown that liver cells with invasive features have high levels of clathrin, a protein whose involvement in liver cancer was unknown until now. Specifically, researchers showed that high expression levels of clathrin correlate with the activation of the pro-tumorigenic pathway of a known hepatic carcinogenesis actor: TGF-. In this sense, the work provides completely new and clinically valuable knowledge when it comes to understanding the complex and controversial role of TGF- in this type of cancer.

TGF-, which belongs to a large group of proteins called cytokines, has a dual role: in normal conditions, or in early stages of carcinogenesis, it plays a tumor suppressive role, promoting cell death and reducing tumor growth. But in advanced stages of liver cancer, where this signaling pathway is highly activated, tumor cells have acquired capabilities to escape its suppressor functions and respond to TGF- by inducing cell migration and invasion, and thus contributing to tumor spreading.

Previous work by the Fabregat group had shown that for this change in cellular behavior to take place, TGF- activates the EGF receptor pathway (EGFR) in tumor cells, whose overexpression and hyperactivity has been associated with a large number of cancers. The new results have shown that clathrin is essential in the endocytosis of EGFR, a decisive step for the activation of this pathway by TGF-. In vitro experiments of this recent work have allowed the IDIBELL researchers to demonstrate that clathrin cell levels determine, via EGFR, the function of TGF-. If the expression of clathrin is eliminated, the cells die. On the contrary, high levels of clathrin promote the proinvasive and tumorigenic character of the cells. The reason for this effect must be found in the functionality of the EGFR pathway: the elimination of clathrin results in an inhibition of this signaling pathway. Researchers have also shown that TGF- is capable of inducing clathrin synthesis, ultimately encouraging a self-stimulation loop.

It is interesting to mention that the study also demonstrates that clathrin expression increases during hepatic tumorigenesis both in humans and mice, and its expression changes the response to TGF- in favor of anti-apoptotic / pro-tumorigenic signals. There is a positive correlation between the expression of TGF- and clathrin in samples of hepatocellular carcinoma patients. Patients expressing high levels of TGF- and clathrin showed a worse prognosis and reduced survival.

According to Dr. Fabregat, "determining the levels of clathrin expression in samples of hepatocellular carcinoma patients can be of great help in selecting those who can be given a therapy based on inhibitors of the TGF- pathway". All healthcare institutions surrounding IDIBELL have actively participated in this study; analyses of human tumors have been carried out by E. Ramos and T. Serrano, of Bellvitge University Hospital. On the other hand, X. Sol and A. Alay, of the Catalan Institute of Oncology, have carried out the bioinformatic treatment of the data. In addition, the Complutense University of Madrid has also made a contribution.

Reference: Caballero-Diaz et al. 2019.Clathrin switches Transforming Growth Factor- role to pro-tumorigenic in liver cancer. Journal of Hepatology. DOI: https://doi.org/10.1016/j.jhep.2019.09.012.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
Cell Membrane Protein Identified as "Crucial" in Development of Liver Cancer - Technology Networks

TIMP1 Is A Potential Key Gene Associated With The Pathogenesis And Pro | OTT – Dove Medical Press

Ru Huang,1,* Kaijing Wang,2,* Lei Gao,1 Wei Gao2

1Department of Heart Failure, Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Peoples Republic of China; 2Department of Colorectal Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Wei GaoDepartment of Colorectal Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Peoples Republic of ChinaEmail yoursgaowei@163.comLei GaoDepartment of Heart Failure, Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Peoples Republic of ChinaEmail gldlykdx@163.com

Purpose: Colorectal cancer (CRC) is the third most frequently diagnosed cancer worldwide. As a high-risk factor for CRC, ulcerative colitis (UC) has been demonstrated to lead to epithelial dysplasia, DNA damage, and eventually cancer. There are approximately 18% of patients with UC may develop CRC.Patients and methods: The gene expression profiles were retrieved from the Gene Expression Omnibus. The Database for Annotation, Visualization and Integrated Discovery was employed to conduct gene annotations. Protein-protein interaction network was constructed by the Search Tool for the Retrieval of Interacting Genes, and further analysed by the Molecular Complex Detection. The correlation between TIMP1 and prognosis was evaluated by the Gene Expression Proling Interactive Analysis. To predict the potential functions of TIMP1, the GeneMANIA, Coremine, and FunRich were employed. After transfection with small interfering RNA targeting TIMP1, cell proliferation, migration, and apoptosis were determined by CCK-8, scratch wound, and Annexin V-FITC/PI assays, respectively.Results: TIMP1, consistently overexpressed in the initiation and progression of UC-associated CRC (ucaCRC), was identified to be a potential biomarker for the prognosis of patients with CRC. Experimental results showed knockdown of TIMP1 could increase the migration, while did not affect the proliferation and apoptosis of RKO cells. The role of TIMP1 in the malignant transformation of ucaCRC was confirmed by using the protein/gene interactions and biological process annotation and validated by analysing the transcription factors targeting TIMP1.Conclusion: TIMP1 is consistently upregulated in the pathological process of ucaCRC and can be a potential biomarker for the worse prognosis of CRC.

Keywords: colitis ulcerative, colorectal neoplasms, high-throughput screening assays, prognosis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the rest here:
TIMP1 Is A Potential Key Gene Associated With The Pathogenesis And Pro | OTT - Dove Medical Press

Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference – GlobeNewswire

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer

WATERTOWN, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and MDMX, prevented chemotherapy-related toxicities in cellular studies and mouse models of cancer without limiting and even enhancing anti-cancer efficacy.

Chemotherapy is widely used to treat and often cure millions of cancer patients each year, but chemotherapy is toxic and commonly causes severe or life-threatening side effects, said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. Based on the findings of our nonclinical studies and mechanism of ALRN-6924, we believe that patients with p53-mutant cancers who are treated with chemotherapy may suffer fewer and less severe chemotherapy-related side effects if ALRN-6924 is administered prior to chemotherapy.

Our nonclinical results show that ALRN-6924 significantly reduces the toxic effects of chemotherapy in normal, healthy bone marrow cells and gastrointestinal tissues, stated Allen Annis, Ailerons SVP of Research. The results of these in vivo studies are impressive and suggest that ALRN-6924 activates the p53 gene to temporarily induce cell cycle arrest and prevent the toxic effects of chemotherapy in normal cells. Importantly, about half of all cancer patients have a mutation in the p53-gene. Our findings suggest that prophylactic use of ALRN-6924 can protect p53-wildtype normal cells while allowing chemotherapy to be effective against p53 mutant cancer cells. With this mechanism, we believe ALRN-6924 may enable a precision-medicine strategy to prevent chemotherapy-related toxicities in patients with p53-mutated cancer.

The results presented at the conference show that low doses of ALRN-6924 trigger reversible cell cycle arrest in human bone marrow cells ex vivo and in mouse bone marrow cells in vivo to limit toxicity caused by topotecan, a chemotherapy used in small-cell lung cancer (SCLC) and other cancer indications. The results also show that gastrointestinal toxicity caused by topotecan is also reduced as a result of pretreatment with ALRN-6924, which we believe could potentially translate to the clinic as an improvement in gastrointestinal side effects of chemotherapy. In three p53-mutant tumor models, the anti-cancer activity of topotecan is not diminished, and in fact the results show that the anti-cancer activity is improved by administering ALRN-6924 prior to topotecan, a result that we believe may be due to stimulation of the immune system, which has previously been shown for ALRN-6924 and other p53-activating agents.

Improving the tolerability of chemotherapy with ALRN-6924 has the potential to reduce dose delays and dose reductions. Such improved chemotherapy delivery and the potential stimulation of the immune system are two independent mechanisms that may enhance the anti-tumor effects of chemotherapy, stated Dr. Vojislav Vukovic, Chief Medical Officer of Aileron. While our first myelopreservation trial for ALRN-6924 is in SCLC patients treated with topotecan, we plan to develop ALRN-6924 as a tumor type-agnostic and chemotherapy-agnostic drug.

Millions of cancer patients worldwide receive chemotherapy each year. Published literature indicates that p53 mutations are found in about 50% of those cancer patients.

ALRN-6924 is currently being evaluated in the dose-optimization phase 1b portion of a Phase 1b/2 myelopreservation trial designed to identify a recommended phase 2 dose for ALRN-6924 and to evaluate the safety and efficacy of ALRN-6924 in preventing or limiting toxicities caused by treatment with topotecan in SCLC patients. Based on Ailerons nonclinical data, and contingent on results from the ongoing dose-optimization phase 1b, the Company plans to expand its clinical program in myelopreservation to include an additional Phase 1b cohort in non-small cell lung cancer patients treated with docetaxel, and a randomized expansion cohort of the Phase 1b SCLC trial to treat patients with alternating cycles of chemotherapy with and without ALRN-6924 (the on/off cohort) where each patient will serve as his/her own control. The Company expects to present key findings from the ongoing dose-optimization Phase 1b SCLC portion of the Phase 1b/2 myelopreservation trial in the second quarter of 2020.

Poster Presentation Details:Conference: 2019 AACR-NCI-EORTC Conference on Molecular Targets and Cancer TherapeuticsPoster Title: The Investigational Peptide Drug ALRN-6924, a Dual Inhibitor of MDMX and MDM2, is an Effective Myelopreservation Agent.

The Aileron poster can be accessed via the following link:http://share.aileronrx.com/posters/Aileron_AACR-NCI-EORTC_2019_Carvajal_Final.pdf

About ALRN-6924ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor that is currently being evaluated as an anti-cancer agent in a Phase 2a clinical trial in combination with Pfizers palbociclib (Ibrance) for the treatment of MDM2-amplified advanced solid tumors, and in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-related toxicities.

About AileronAileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides. The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in drug candidates like ALRN-6924. Our current focus is to improve the standard of care for patients with cancer by developing safe and effective therapies and cancer supportive care treatments that leverage our proprietary peptide platform. For more information, visit http://www.aileronrx.com, and for more information about our clinical trials please visit http://www.clinicaltrials.gov.

Forward-Looking StatementsStatements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Companys strategy and clinical development plans. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Ailerons cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated, including the additional myelopreservation trials planned; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Ailerons product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the period ended June 30, 2019, filed on August 6, 2019, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Investors:Aileron TherapeuticsRick Wanstall, VP Finance & Operations617-995-0900rwanstall@aileronrx.com

Hans C. VitzthumLifeSci Advisors, LLC.617-430-7578hans@lifesciadvisors.com

Read more here:
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference - GlobeNewswire